395 related articles for article (PubMed ID: 24969162)
1. Rare breast cancer subtypes: histological, molecular, and clinical peculiarities.
Dieci MV; Orvieto E; Dominici M; Conte P; Guarneri V
Oncologist; 2014 Aug; 19(8):805-13. PubMed ID: 24969162
[TBL] [Abstract][Full Text] [Related]
2. Invasive breast cancer: a significant correlation between histological types and molecular subgroups.
Caldarella A; Buzzoni C; Crocetti E; Bianchi S; Vezzosi V; Apicella P; Biancalani M; Giannini A; Urso C; Zolfanelli F; Paci E
J Cancer Res Clin Oncol; 2013 Apr; 139(4):617-23. PubMed ID: 23269487
[TBL] [Abstract][Full Text] [Related]
3. Ki67 index in intrinsic breast cancer subtypes and its association with prognostic parameters.
Hashmi AA; Hashmi KA; Irfan M; Khan SM; Edhi MM; Ali JP; Hashmi SK; Asif H; Faridi N; Khan A
BMC Res Notes; 2019 Sep; 12(1):605. PubMed ID: 31547858
[TBL] [Abstract][Full Text] [Related]
4. Special types of invasive breast cancer, with clinical implications.
Page DL
Am J Surg Pathol; 2003 Jun; 27(6):832-5. PubMed ID: 12766589
[TBL] [Abstract][Full Text] [Related]
5. Refinement of breast cancer classification by molecular characterization of histological special types.
Weigelt B; Horlings HM; Kreike B; Hayes MM; Hauptmann M; Wessels LF; de Jong D; Van de Vijver MJ; Van't Veer LJ; Peterse JL
J Pathol; 2008 Oct; 216(2):141-50. PubMed ID: 18720457
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic and prognostic evaluation of invasive breast carcinoma molecular subtypes and GATA3 expression.
Demir H; Turna H; Can G; Ilvan S
J BUON; 2010; 15(4):774-82. PubMed ID: 21229645
[TBL] [Abstract][Full Text] [Related]
7. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
Lancet; 1997 May; 349(9064):1505-10. PubMed ID: 9167459
[TBL] [Abstract][Full Text] [Related]
8. Novel prognostic markers for patients with triple-negative breast cancer.
Zhou L; Li K; Luo Y; Tian L; Wang M; Li C; Huang Q
Hum Pathol; 2013 Oct; 44(10):2180-7. PubMed ID: 23845466
[TBL] [Abstract][Full Text] [Related]
9. Ki-67 is a prognostic marker for hormone receptor positive tumors.
Pérez-López ME; García-Gómez J; Alves MT; Paradela A; García-Mata J; García-Caballero T
Clin Transl Oncol; 2016 Oct; 18(10):996-1002. PubMed ID: 26742937
[TBL] [Abstract][Full Text] [Related]
10. Genomic profiling of histological special types of breast cancer.
Horlings HM; Weigelt B; Anderson EM; Lambros MB; Mackay A; Natrajan R; Ng CK; Geyer FC; van de Vijver MJ; Reis-Filho JS
Breast Cancer Res Treat; 2013 Nov; 142(2):257-69. PubMed ID: 24162157
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer pathology: the impact of molecular taxonomy on morphological taxonomy.
Masuda S
Pathol Int; 2012 May; 62(5):295-302. PubMed ID: 22524656
[TBL] [Abstract][Full Text] [Related]
12. [BRCA1- and BRCA2- associated breast carcinomas].
Ahrens P; Kreipe HH
Pathologe; 2009 Dec; 30 Suppl 2():207-9. PubMed ID: 19795125
[TBL] [Abstract][Full Text] [Related]
13. Can a phenotype for recessive inheritance in breast cancer be defined?
Ellberg C; Jönsson G; Olsson H
Fam Cancer; 2010 Dec; 9(4):525-30. PubMed ID: 20549370
[TBL] [Abstract][Full Text] [Related]
14. The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast.
Narbe U; Sjöström M; Forsare C; Bendahl PO; Alkner S; Leeb-Lundberg LMF; Lövgren K; Rydén L; Ingvar C; Fernö M
Breast Cancer Res Treat; 2019 Jun; 175(2):305-316. PubMed ID: 30796653
[TBL] [Abstract][Full Text] [Related]
15. Expression of metalloproteases and their inhibitors in different histological types of breast cancer.
Del Casar JM; González-Reyes S; González LO; González JM; Junquera S; Bongera M; García MF; Andicoechea A; Serra C; Vizoso FJ
J Cancer Res Clin Oncol; 2010 Jun; 136(6):811-9. PubMed ID: 19916023
[TBL] [Abstract][Full Text] [Related]
16. Unique clinicopathological features of metaplastic breast carcinoma compared with invasive ductal carcinoma and poor prognostic indicators.
Song Y; Liu X; Zhang G; Song H; Ren Y; He X; Wang Y; Zhang J; Zhang Y; Sun S; Liang X; Sun Q; Pang D
World J Surg Oncol; 2013 Jun; 11():129. PubMed ID: 23738706
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society.
Iwase H; Kurebayashi J; Tsuda H; Ohta T; Kurosumi M; Miyamoto K; Yamamoto Y; Iwase T
Breast Cancer; 2010 Apr; 17(2):118-24. PubMed ID: 19466512
[TBL] [Abstract][Full Text] [Related]
18. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.
Fernandes RC; Bevilacqua JL; Soares IC; Siqueira SA; Pires L; Hegg R; Carvalho FM
Histopathology; 2009 Sep; 55(3):346-52. PubMed ID: 19723150
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer.
Kuo SH; Yang SY; You SL; Lien HC; Lin CH; Lin PH; Huang CS
Oncotarget; 2017 Mar; 8(13):20925-20938. PubMed ID: 28178648
[TBL] [Abstract][Full Text] [Related]
20. Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters.
Naidu R; Wahab NA; Yadav MM; Kutty MK
Oncol Rep; 2002; 9(2):409-16. PubMed ID: 11836618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
